Key secondary endpoints also demonstrated statistically significant and clinically meaningful benefits with Gazyva
Sotyktu continues to demonstrate consistent efficacy and safety across rheumatic conditions
Arora brings over 30 years of experience in the pharmaceutical and healthcare industry
Partnership combines MilliporeSigma’s chemistry and organoid expertise with Promega’s assay technologies
Agreement adds a new preclinical ADC with potential for enhanced anti-tumour activity and best-in-class profile
Bioconjugation capability to complement commercial payload, linker, and monoclonal antibody services
Efdoralprin Alfa was well tolerated, with a safety profile comparable to plasma-derived therapy
Long-term OGSIVEO treatment for up to four years associated with further tumor reductions, increased objective response rate, sustained symptom improvement, and consistent safety profile
OS is a key secondary endpoint of the 948-patient study, which is evaluating whether adding AstraZeneca's PD-L1 inhibitor to standard FLOT chemotherapy
Glenmark’s Ropivacaine Hydrochloride Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug Naropin Injection of Fresenius Kabi USA
Subscribe To Our Newsletter & Stay Updated
